# Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

> **NCT04997317** · PHASE1,PHASE2 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 18 (estimated)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over)
- **DRUG:** 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4
- **DRUG:** 177Lu-DOTA-JR11 (Phase I/II)

## Key facts

- **NCT ID:** NCT04997317
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04997317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04997317, "Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04997317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*